Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced the submission of a supplemental New Drug Application (sNDA) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE